Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine

• Main Authors: Sofía Calleja (Author), Pablo Zubiaur (Author), Dolores Ochoa (Author), Gonzalo Villapalos-García (Author), Gina Mejia-Abril (Author), Paula Soria-Chacartegui (Author), Marcos Navares-Gómez (Author), Alejandro de Miguel (Author), Manuel Román (Author), Samuel Martín-Vílchez (Author), Francisco Abad-Santos (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Venlafaxine pharmacokinetic variability and pharmacotherapy outcomes are well known to be related to CYP2D6 pharmacogenetic phenotype. In contrast, scarce pharmacogenetic information is available nowadays concerning desvenlafaxine, its active metabolite first marketed in 2012. The aim of this study...